Role of the N- and C-Terminal Domains in Binding of Apolipoprotein E Isoforms to Heparan Sulfate and Dermatan Sulfate: A Surface Plasmon Resonance Study
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index; 9 of the 59 sources its claims cite were checked for support.
Abstract
The ability of apolipoprotein E (apoE) to bind to cell-surface glycosaminoglycans (GAGs) is important for lipoprotein remnant catabolism. Using surface plasmon resonance, we previously showed that the binding of apoE to heparin is a two-step process; the initial binding involves fast electrostatic interaction, followed by a slower hydrophobic interaction. Here we examined the contributions of the N- and C-terminal domains to each step of the binding of apoE isoforms to heparan sulfate (HS) and dermatan sulfate (DS). ApoE3 bound to less sulfated HS and DS with a decreased favorable free energy of binding in the first step compared to heparin, indicating that the degree of sulfation has a major effect on the electrostatic interaction of GAGs with apoE. Mutation of a key Lys residue in the N-terminal heparin binding site of apoE significantly affected this electrostatic interaction. Progressive truncation of the C-terminal alpha-helical regions which favors the monomeric form of apoE3 greatly weakened the ability of apoE3 to bind to HS, with a much reduced favorable free energy of binding of the first step, suggesting that the C-terminal domain contributes to the GAG binding of apoE by the oligomerization effect. In agreement with this, dimerization of the apoE3 N-terminal fragment via disulfide linkage restored the electrostatic interaction of apoE with HS. Significantly, apoE4 exhibited much stronger binding to HS and DS than apoE2 or apoE3 in both lipid-free and lipidated states, perhaps resulting from enhanced electrostatic interaction through the N-terminal domain. This isoform difference in GAG binding of apoE may be physiologically significant such as in the retention of apoE-containing lipoproteins in the arterial wall.
Overview
CoChat Summary
TL;DR
Surface plasmon resonance shows that apoE binds heparan sulfate (HS) and dermatan sulfate (DS) via a two-step process, with the N-terminal domain dominating the initial electrostatic interaction and the C-terminal domain enhancing binding through oligomerization. ApoE4 binds HS and DS more strongly than apoE2 or apoE3 in both lipid-free and lipidated states.
Key findings
- Binding of apoE3 to HS and DS was two-step; compared with heparin, less sulfated HS and DS had slower first association and lower favorable free energy for the first step. Sulfation was 1.6, 0.7, and 0.7 sulfate groups per disaccharide for heparin, HS, and DS, respectively.
- The N-terminal heparin-binding-site mutation K146E greatly reduced HS/DS binding, whereas K233E behaved like wild-type. For HS binding, Rmax values were 1300, 180, and 1020 RU for apoE3 WT, K146E, and K233E, respectively.
- C-terminal truncation that favors monomeric apoE3 reduced HS binding and the favorable free energy of the first step, but Rmax values were not significantly different among full-length, 1–272, 1–260, and 1–250 apoE3 (880, 840, 1200, and 710 RU, respectively). Dimerization of the apoE3 22-kDa fragment restored kinetics comparable to full-length apoE3 (Kd: 0.18 ± 0.03 μM for apoE3, 6.2 ± 2.9 μM for 22-kDa monomer, and 0.61 ± 0.12 μM for 22-kDa dimer).
- ApoE4 showed two- to three-fold higher binding to HS and DS than apoE2 or apoE3 in lipid-free and lipidated states. Rmax values for lipid-free apoE2, apoE3, and apoE4 were 670, 810, and 1210 RU; for DMPC discs they were 360, 320, and 635 RU. The apoE4 E255A mutant still bound more than apoE3.
Methods
- SPR measurements used a Biacore X instrument with biotinylated GAG immobilized on a SA chip; apoE samples were flowed over the surface, and sensorgrams were globally fitted to a two-state binding model.
- Recombinant human apoE2, apoE3, apoE4, their 22-kDa fragments, K146E/K233E mutants, C-terminal truncation mutants (Δ251–299, Δ261–299, Δ273–299), a dimerized apoE3 22-kDa fragment, and DMPC discoidal complexes were prepared and analyzed.
- Far-UV circular dichroism and Trp fluorescence were used to assess conformation and urea-induced denaturation; statistical comparisons used t-tests with GraphPad Prism 5.0.
Limitations
- The paper states no formal limitations section.
- Evident from the text: several supporting analyses, including NaCl-dependence of binding, hydrophobic exposure upon dimerization, and some CD/urea data, are reported as “data not shown,” limiting independent assessment.
- Evident from the text: the study uses recombinant apoE and isolated biotinylated GAG on an SPR chip, which may not fully reproduce cell-surface proteoglycan presentation or the complex extracellular matrix environment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 0 Not valid · 31 Not checked · 40 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“quantitative information on the interaction with various GAG molecules is limited (26, 34).”
What the sources say
- Partly supportedcites [26] Libeu C. P., 2001, J. Biol. Chem. sourceExperimental — accuracy not yet measured
Our copy nowhere states that quantitative information on apoE's interaction with various GAG molecules is limited; the passages that come closest address adjacent points. In the Results/Discussion section on measuring heparin-binding activities, the authors note that the heparin-binding activities of apoE K146E, apoE2 (R158C), apoE R142C and apoE R145C 'have been measured by different methods (21-23)' so that a direct comparison with one technique was needed — i.e. limited/comparable quantitative data for apoE variants, not for various GAGs. Another passage (Experimental Procedures/Discussion, citing Shuvaev et al.) says prior SPR measurements of the glycosaminoglycan binding affinity of apoE were done in phosphate buffer, which in their hands greatly reduces the affinities, questioning those quantitative values. Against the claim, the same paper itself reports quantitative-style GAG specificity data across several GAG molecules (heparin, bovine liver heparan sulfate, human aorta heparan sulfate, chondroitin sulfate, dermatan sulfate, N-desulfated heparin; RESULTS, Polysaccharide-binding Assay), so the 'limited' framing is the citing authors' generalization rather than something this source states for various GAGs. (LLM, conf=0.66)
- Supportedcites [34] Shuvaev V. V., 1999, FEBS Lett. source
The Introduction (p. 353) frames the work as the first characterization of apoE-GAG kinetics by SPR ('In the present work... we studied and characterized the kinetics of apoE-GAG interactions'), treating prior evidence as functional/qualitative rather than quantitative ('substantial evidence has been obtained for involving the heparin-binding activity of apoE in lipid metabolism...'). The Discussion reinforces this: earlier work had only shown that extensively sulfated GAGs bind apoE-containing emulsions with high affinity versus low-sulfated dermatan/chondroitin sulfate [27], and quantitative K D comparisons are drawn from other proteins (lipoprotein lipase, K D = 0.3 nM). No passage states the limitation in so many words, but our copy clearly treats quantitative apoE-GAG data as scarce, which supports this broad background statement. (LLM, conf=0.80)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In contrast to the dominant role of the N-terminal site in apoE to GAG binding, the C-terminal site (basic residues around lysine 233) is not available for the interaction of full-length apoE with GAG (Fig. 4) (27, 28).”
What the sources say
- Not checked yetcites [27] Saito H., 2003, J. Biol. Chem. source
- Supportedcites [28] Futamura M., 2005, J. Biol. Chem. source
The introductory passage identifies the C-terminal heparin-binding site around lysine 233 and states that, in intact apoE, only the N-terminal site is available for interaction in both lipid-free and lipidated states. The lysine-mutation results also report that the K233E mutant binds heparin similarly to wild type. Page numbers were not supplied. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Since apoE4 has a lesser propensity to self-associate than apoE3 in solution (47) and the number of apoE molecules on DMPC discs is similar among apoE isoforms (52), it is unlikely that the higher ability of binding of apoE4 to GAG is due to the cooperative effects of the heparin binding sites.”
What the sources say
- Supportedcites [47] Sakamoto T., 2008, Biochemistry source
The citation (47) is attached to the premise that apoE4 has a lesser propensity to self-associate than apoE3 in solution, and our copy states exactly that: the Abstract concludes 'apoE4 self-associates less and binds less than apoE3 to HDL surfaces', the Results (Gel Filtration Chromatography) report that full-length apoE3 and apoE4 exist as monomeric and tetrameric forms 'with apoE4 being more monomeric', and the Discussion states 'ApoE3 favors a tetrameric form whereas apoE4 tends to be more monomeric'. The paper does qualify this (the effect was seen at its low 5 µg/ml concentration and is contrary to earlier reports credited to refs 17 and 43), but its own conclusion matches the claim. The heparin/GAG cooperativity conclusion is the citing authors' own inference; our copy contains no passage on glycosaminoglycan or heparin binding (searched: heparin, glycosaminoglycan, GAG), and the DMPC-disc stoichiometry point is attributed to a separate citation (52). (LLM, conf=0.86)
- Not checked yetcites [52] Schneeweis L. A., 2005, Biochemistry source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, such a hydrophobic exposure contributes to the second step of GAG binding (28)”
What the sources say
- Partly supportedcites [28] Futamura M., 2005, J. Biol. Chem. sourceExperimental — accuracy not yet measured
In “Two-step Mechanism of Binding of ApoE to Heparin,” the authors report that a mutant exposing a hydrophobic surface showed an increased contribution from the second binding step. They say this *implies* that hydrophobic interactions contribute to apoE–heparin binding at that step. The claim states the mechanism as fact and extends it from heparin to GAG binding generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The reduction of this free energy from the wild-type (1.5 and 1.3 kcal/mol for HS and DS, respectively) was much lower than that in heparin (2.7 kcal/mol) (Fig. 6 in ref 28).”
What the sources say
- Partly supportedcites [28] Futamura M., 2005, J. Biol. Chem. sourceExperimental — accuracy not yet measured
The section on lysine mutations (Fig. 6B; page unavailable) reports a decrease in favorable binding free energy relative to wild type for apoE mutants binding heparin. Our copy does not report the claimed 1.5 and 1.3 kcal/mol reductions for HS and DS, or give 2.7 kcal/mol as the heparin reduction; it therefore does not establish the numerical comparison. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
39 more claims
Create a free account to see all 79 claims and to verify the 50 references still open.
- It may state two separate claims as one. 25
- Probably not a substantial claim. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HSPG has been suggested to promote Aβ aggregation and neuronal uptake of extracellular tau; and ApoE-binding may be necessary for some of these effects15,16.”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By contrast, APOE4 has increased binding affinity (up to two-fold) for heparin and HSPG over APOE3 (refs. 32–35).”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is important to note that HSPGs binding studies have shown that apoE4 had higher affinity than apoE3, apoE2 and apoE3 Christchurch, 29 and antibodies raised against the receptor‐binding region mimicked the protective effect of apoE2 and apoE3 Christchurch, 26”
From APOE and dementia – resequencing and genotyping in 105,597 individuals (2020) · cites this paper as [29]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ RESULTS
“apoE3 3.6 ± 0.6 2.5 ± 0.8 3.1 ± 1.0 4.2 ± 0.8 15 7.4 0.18 ± 0.03”
§ Abstract
“the overall equilibrium binding constant is calculated as KA = K1(1 + K2) and Kd = 1/KA.”
Citations
Cites
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
The Response-to-Retention Hypothesis of Early Atherogenesis
Williams, K. J., & Tabas, I. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.551 · Cited by 1,413
Apolipoprotein E: Structure-Function Relationships
Weisgraber, K. H. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60642-7 · Cited by 830
Mahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
Three-Dimensional Structure of the LDL Receptor-Binding Domain of Human Apolipoprotein E
Wilson, C., Wardell, M. R., Weisgraber, K. H., Mahley, R. W., & Agard, D. A. (1991) · Science · doi:10.1126/science.2063194 · Cited by 678
Apolipoprotein E structure: insights into function
Hatters, D. M., Peters-Libeu, C. A., & Weisgraber, K. H. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.06.008 · Cited by 583 · cited 1×
“ApoE contains two independently folded functional domains; these are a 22-kDa N-terminal domain (residues 1–191) and a 10-kDa C-terminal domain (residues 216–299) linked by a hinge region (18,19).”
BackgroundKarlsson, R., & Fält, A. (1997) · Journal of Immunological Methods · doi:10.1016/s0022-1759(96)00195-0 · Cited by 568
Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors
Myszka, D. G. (1997) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(97)80157-7 · Cited by 552
Hepatic uptake of chylomicron remnants
Cooper, A. D. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34932-4 · Cited by 499
Heparan sulfate: a piece of information
Salmivirta, M., Lidholt, K., & Lindahl, U. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.11.8836040 · Cited by 439
Holtzman, D. M., Pitas, R. E., Kilbridge, J., Nathan, B., Mahley, R. W., Bu, G., & Schwartz, A. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.21.9480 · Cited by 349
Interaction of an apolipoprotein (apoLP-alanine) with phosphatidylcholine
Morrisett, J. D., David, J. S. K., Pownall, H. J., & Gotto, A. M. (1973) · Biochemistry · doi:10.1021/bi00731a008 · Cited by 331
Human Apolipoprotein E4 Domain Interaction
Dong, L.-M., & Weisgraber, K. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.32.19053 · Cited by 318
[13] Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors
Morton, T. A., & Myszka, D. G. (1998) · Methods in Enzymology · doi:10.1016/s0076-6879(98)95044-3 · Cited by 308
Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3.
Weisgraber, K. H., Rall, S. C., Mahley, R. W., Milne, R. W., Marcel, Y. L., & Sparrow, J. T. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35898-2 · Cited by 240
Aggerbeck, L. P., Wetterau, J. R., Weisgraber, K. H., Wu, C. S., & Lindgren, F. T. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68779-4 · Cited by 229
MacArthur, J. M., Bishop, J. R., Stanford, K. I., Wang, L., Bensadoun, A., Witztum, J. L., & Esko, J. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29154 · Cited by 216 · cited 1×
“The various anti-atherogenic functions of apoE, such as facilitated remnant lipoprotein uptake by the liver (8,50) and cholesterol efflux from macrophages (16,17), are achieved through its interaction with cell-surface GAG.”
BackgroundWesterlund, J. A., & Weisgraber, K. H. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82318-3 · Cited by 164 · cited 1×
“The N-terminal domain is folded into a four-helix bundle of amphipathic α-helices and contains the LDLR binding region (around residues 136–150 in helix 4) (20), whereas the C-terminal domain contains amphipathic α-helices that are involved in binding to lipoproteins with high affinity (21,22).”
BackgroundLewis, K. E., Kirk, E. A., McDonald, T. O., Wang, S., Wight, T. N., O’Brien, K. D., & Chait, A. (2004) · Circulation · doi:10.1161/01.cir.0000136819.93989.e1 · Cited by 163
Mahley, R. W., & Huang, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30889 · Cited by 159 · cited 1×
“heparan sulfate (HS) in the liver (2).”
Ji, Z.-S., Pitas, R. E., & Mahley, R. W. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13452 · Cited by 134
Cardin, A. D., Hirose, N., Blankenship, D. T., Jackson, R. L., Harmony, J. A. K., Sparrow, D. A., & Sparrow, J. T. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(86)80489-2 · Cited by 123
Turbidimetry of inorganic sulfate, ester sulfate, and total sulfur in urine.
Lundquist, P., Mårtensson, J., Sörbo, B. H., et al. (1980) · Clinical Chemistry · doi:10.1093/clinchem/26.8.1178 · Cited by 118
Lipid Binding-induced Conformational Change in Human Apolipoprotein E
Saito, H., Dhanasekaran, P., Baldwin, F., Weisgraber, K. H., Lund-Katz, S., & Phillips, M. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106337200 · Cited by 113
Self-citationNew Insights into the Heparan Sulfate Proteoglycan-binding Activity of Apolipoprotein E
Libeu, C. P., Lund-Katz, S., Phillips, M. C., Wehrli, S., Hernáiz, M. J., Capila, I., Linhardt, R. J., Raffaı̈, R. L., Newhouse, Y. M., Zhou, F., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104746200 · Cited by 113
Self-citationDesign of Peptides with High Affinities for Heparin and Endothelial Cell Proteoglycans
Verrecchio, A., Germann, M. W., Schick, B. P., Kung, B., Twardowski, T., & San Antonio, J. D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.7701 · Cited by 102 · cited 1×
“This notion that multiple binding sites of apoE molecules increase the GAG binding is consistent with the previous study of peptides including heparin binding consensus sequences showing that multiple copies of the heparin binding site enhance the binding affinity through cooperativity effects (51).”
ResultInteraction of the N-Terminal Domain of Apolipoprotein E4 with Heparin
Dong, J., Peters-Libeu, C. A., Weisgraber, K. H., Segelke, B. W., Rupp, B., Capila, I., Hernáiz, M. J., LeBrun, L. A., & Linhardt, R. J. (2001) · Biochemistry · doi:10.1021/bi002417n · Cited by 99
Experimental Design for Analysis of Complex Kinetics Using Surface Plasmon Resonance
Lipschultz, C. A., Li, Y., & Smith‐Gill, S. J. (2000) · Methods · doi:10.1006/meth.1999.0924 · Cited by 93
Two-step Mechanism of Binding of Apolipoprotein E to Heparin
Futamura, M., Dhanasekaran, P., Handa, T., Phillips, M. C., Lund-Katz, S., & Saito, H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411719200 · Cited by 91
Self-citationCharacterization of the Heparin Binding Sites in Human Apolipoprotein E
Saito, H., Dhanasekaran, P., Nguyen, D., Baldwin, F., Weisgraber, K. H., Wehrli, S., Phillips, M. C., & Lund-Katz, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213207200 · Cited by 90
Self-citationEffects of Polymorphism on the Lipid Interaction of Human Apolipoprotein E
Saito, H., Dhanasekaran, P., Baldwin, F., Weisgraber, K. H., Phillips, M. C., & Lund-Katz, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304814200 · Cited by 89
Self-citationEbara, T., Conde, K., Kako, Y., Liu, Y., Xu, Y., Ramakrishnan, R., Goldberg, I. J., & Shachter, N. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8283 · Cited by 86
A Monomeric, Biologically Active, Full-Length Human Apolipoprotein E
Zhang, Y., Vasudevan, S., Sojitrawala, R., Zhao, W., Cui, C., Xu, C., Fan, D., Newhouse, Y., Balestra, R., Jerome, W. G., et al. (2007) · Biochemistry · doi:10.1021/bi700672v · Cited by 79
Mechanism of lipoprotein retention by the extracellular matrix
Gustafsson, M., & Borén, J. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200410000-00003 · Cited by 75
Melittin Interaction with Sulfated Cell Surface Sugars
Klocek, G., & Seelig, J. (2008) · Biochemistry · doi:10.1021/bi702258z · Cited by 60
Swertfeger, D. K., & Hui, D. Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102357200 · Cited by 59
Effects of Lipid Interaction on the Lysine Microenvironments in Apolipoprotein E
Lund-Katz, S., Zaiou, M., Wehrli, S., Dhanasekaran, P., Baldwin, F., Weisgraber, K. H., & Phillips, M. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005265200 · Cited by 54
Self-citationSakamoto, T., Tanaka, M., Vedhachalam, C., Nickel, M., Nguyen, D., Dhanasekaran, P., Phillips, M. C., Lund-Katz, S., & Saito, H. (2008) · Biochemistry · doi:10.1021/bi701923h · Cited by 54
Self-citationHara, M., Matsushima, T., Satoh, H., Iso-o, N., Noto, H., Togo, M., Kimura, S., Hashimoto, Y., & Tsukamoto, K. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054199.78458.4b · Cited by 53 · cited 3×
“The various anti-atherogenic functions of apoE, such as facilitated remnant lipoprotein uptake by the liver (8,50) and cholesterol efflux from macrophages (16,17), are achieved through its interaction with cell-surface GAG.”
BackgroundGlycosaminoglycan-lipoprotein interaction
Olsson, U., Östergren-Lundén, G., & Moses, J. (2001) · Glycoconjugate Journal · doi:10.1023/a:1021155518464 · Cited by 46
Effect of Carboxyl-Terminal Truncation on Structure and Lipid Interaction of Human Apolipoprotein E4
Tanaka, M., Vedhachalam, C., Sakamoto, T., Dhanasekaran, P., Phillips, M. C., Lund-Katz, S., & Saito, H. (2006) · Biochemistry · doi:10.1021/bi060023b · Cited by 43 · cited 2×
“The mutations in apoE to create K146E and K233E, and the truncated forms (Δ251–299, Δ261–299 and Δ273–299) were made using PCR methods as described (27,37).”
BackgroundMethodSelf-citationEffects of polymorphism on the microenvironment of the LDL receptor-binding region of human apoE
Lund-Katz, S., Wehrli, S., Zaiou, M., Newhouse, Y., Weisgraber, K. H., & Phillips, M. C. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31612-6 · Cited by 40
Self-citationStructural Analysis of Lipoprotein E Particles
Schneeweis, L. A., Koppaka, V., Lund-Katz, S., Phillips, M. C., & Axelsen, P. H. (2005) · Biochemistry · doi:10.1021/bi050872j · Cited by 39 · cited 2×
“Since apoE4 has a lesser propensity to self-associate than apoE3 in solution (47) and the number of apoE molecules on DMPC discs is similar among apoE isoforms (52), it is unlikely that the higher ability of binding of apoE4 to GAG is due to the cooperative effects of the heparin binding sites.”
BackgroundSelf-citationLin, Y., Pixley, R. A., & Colman, R. W. (2000) · Biochemistry · doi:10.1021/bi992048z · Cited by 32
Lin, C.-Y., Huang, Z. H., & Mazzone, T. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31603-5 · Cited by 32
Loss of Heparan N-Sulfotransferase in Diabetic Liver
Williams, K. J., Liu, M.-L., Zhu, Y., Xu, X., Davidson, W. R., McCue, P., & Sharma, K. (2005) · Diabetes · doi:10.2337/diabetes.54.4.1116 · Cited by 31
Evidence for differential effects of apoE3 and apoE4 on HDL metabolism
Hopkins, P. C. R., Huang, Y., McGuire, J. G., & Pitas, R. E. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200172-jlr200 · Cited by 31
Gonçalves, E., Kitas, E., & Seelig, J. (2006) · Biochemistry · doi:10.1021/bi052221t · Cited by 28 · cited 1×
“Indeed, analysis of the dependence of affinity constants on sodium chloride concentration (53,54) indicated that the numbers of purely ionic interactions involved in the HS binding of apoE4 is about 3-fold larger than that for apoE3 (data not shown).”
BackgroundShuvaev, V. V., Laffont, I., & Siest, G. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01285-5 · Cited by 27
Bazin, H. G., Marques, M. A., Owens, A. P., Linhardt, R. J., & Crutcher, K. A. (2002) · Biochemistry · doi:10.1021/bi025817e · Cited by 22
Olin-Lewis, K., Benton, J. L., Rutledge, J. C., Baskin, D. G., Wight, T. N., & Chait, A. (2002) · Circulation Research · doi:10.1161/01.res.0000024691.82864.f0 · Cited by 19 · cited 2×
“The interaction of apoE with CS and/or DS proteoglycans is responsible for the retention of high density lipoproteins (HDL) on the extracellular matrix of arterial smooth muscle cells (14), and the uptake of βvery low density lipoprotein in the brain (15).”
BackgroundKlezovitch, O., Formato, M., Cherchi, G. M., Weisgraber, K. H., & Scanu, A. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909644199 · Cited by 17
Burgess, J. W., Liang, P., Vaidyanath, C., & Marcel, Y. L. (1999) · Biochemistry · doi:10.1021/bi9819778 · Cited by 16 · cited 1×
“A major pool of apoE on the surface of human liver cells is associated with CS proteoglycans (13).”
BackgroundRaut, S., & Gaffney, P. J. (1996) · Thrombosis Research · doi:10.1016/0049-3848(96)00024-2 · Cited by 15
Klezovitch, O., & Scanu, A. M. (2001) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00121-9 · Cited by 6
Role of chondroitin sulphate in the uptake of β‐VLDL by brain cells
Rapp, A., & Hüttinger, M. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04313.x · Cited by 4
Capila, I., & Linhardt, R. J. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020201)41:3<390::aid-anie390>3.0.co;2-b · cited 1×
“Although the variations in the distribution of acidic groups in different types of GAG (31) are likely to influence the interaction with apoE (32,33), quantitative information on the interaction with various GAG molecules is limited (26,34).”
BackgroundShaping animal body plans in development and evolution by modulation of Hox expression patterns
(1998) · doi:10.1002/(sici)1521-1878(199802)20:2
Cited by
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
“ApoE also interacts with heparan sulfate proteoglycans (HSPG) [47] and binds heparin through two separate sites [48].”
BackgroundArboleda-Velasquez, J. F., Lopera, F., O’Hare, M., Delgado-Tirado, S., Marino, C., Chmielewska, N., Saez-Torres, K. L., Amarnani, D., Schultz, A. P., Sperling, R. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0611-3 · Cited by 598
Johnson, E. C. B., Carter, E. K., Dammer, E. B., Duong, D. M., Gerasimov, E. S., Liu, Y., Liu, J., Betarbet, R., Ping, L., Yin, L., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-021-00999-y · Cited by 561
“…interact with heparan sulfate proteoglycans, and loss of this binding interaction has been suggested as a possible mechanism for the remarkable protection afforded by the ApoE Christchurch loss-of-function mutation recently described in a presenilin-1 autosomal dominant AD mutation carrier 43,44 .”
Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis
Chen, Y., Strickland, M. R., Soranno, A., & Holtzman, D. M. (2021) · Neuron · doi:10.1016/j.neuron.2020.10.008 · Cited by 298
“On the other hand, a study applying fluorescence cross-correlation spectroscopy (FCCS) combined with alternating laser excitation (ALEX) characterized this interaction in solution, overcoming the immobilization restraint in SPR and noise signal from self-association in EPR assay (Ly et al., 2013).”
Fernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00566-4 · Cited by 278
Metadata
- Authors
- Yamauchi, Y., Deguchi, N., Takagi, C., Tanaka, M., Dhanasekaran, P., Nakano, M., Handa, T., Phillips, M. C., Lund-Katz, S., & Saito, H.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan, Department of Biophysical Chemistry, Kobe Pharmaceutical University, Kobe 658-8558, Japan, and Lipid Research Group, The Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-4318
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-05-29
- Volume
- 47
- Issue
- 25
- Pages
- 6702-6710
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- PMC
- PMC2844924
- OpenAlex
- W1987210223
- Cited by
- 53
- References
- 59
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 5 · 2023: 8 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 3 · 2017: 3 · 2016: 1 · 2015: 1 · 2014: 2 · 2012: 1
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL056083, HL-56083)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- apolipoprotein E, apolipoprotein E isoforms, heparan sulfate, dermatan sulfate, glycosaminoglycan binding, N-terminal domain, C-terminal domain, electrostatic interactions, hydrophobic interactions, degree of sulfation, APOE3, APOE ε4, APOE2, oligomerization, disulfide bonds
- MeSH terms
- Animals, Apolipoproteins E, Binding Sites, Circular Dichroism, Dermatan Sulfate, Disulfides, Heparan Sulfate, Humans, Lysine, Mutation, Protein Binding, Swine, Surface Plasmon Resonance, Apolipoprotein E3, Apolipoprotein E4, Protein Multimerization, Static Electricity, Hydrophobic and Hydrophilic Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.